Rationale: Our previous studies in children with acute lung injury/ acute respiratory distress syndrome demonstrated improved outcomes with exogenous surfactant (calfactant) administration. Sample sizes in those studies were small, however, and the subject populations heterogeneous, thus making recommendations tenuous.
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In three previous studies in children, we demonstrated that the administration of bovine natural surfactant, calfactant (Infasurf; ONY Pharmaceuticals, Amherst, NY), was associated with immediate improvement in oxygenation and, in the two studies with controls, better long-term outcomes, including decreased mortality (10) (11) (12) . In our most recent study (12) , the post hoc analysis demonstrated that improvement with surfactant administration was confined to the subjects with direct lung injury (lung injury that originates on the alveolar side of the alveolar-capillary membrane, such as pneumonia, aspiration, or near drowning). Consequently, the investigators elected to focus this investigation on that patient population. In view of the success of these earlier pediatric trials and the need to investigate possible efficacy in a larger but more homogeneous population, the investigators embarked on a multi-institutional trial of calfactant in both adults and children with direct ALI/ARDS. This article presents the results of the pediatric arm of the trial.
METHODS
Subjects were recruited from July 2008 to July 2010 from the ICUs of 24 children's hospitals in six countries (Appendix 1). The study, registered with clinicaltrials.gov (identifier NCT00682500), was performed in accordance with the Declaration of Helsinki (1996) and the rules of the International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use-Good Clinical Practice Consolidated Guideline. All patients or their legal representatives provided written informed consent and independent ethics committees or institutional review boards at each participating center approved the study protocol. An independent Data and Safety Monitoring Board (DSMB) monitored the study throughout. The study was stopped at the request of the sponsor, Pneuma Pharmaceuticals (Amherst, NY) after the planned second interim analysis at 400 subjects (combined adult and pediatric subjects) because of presumed futility.
Patient Population
Study coordinators at each site screened all ICU admissions. Children were eligible for the study if they were 37 weeks postconception to 18 years old, they met the American-European Consensus Conference definition of ALI/ARDS (13), they had direct lung injury (injury originating on the alveolar side of the alveolar capillary membrane), they were within 48 hours of the initiation of mechanical ventilation, they did not have significant other organ failure or chronic lung disease, and/or the scope and duration of their care were not limited by nonrespiratory disease. In the event of a question regarding eligibility, participating investigators were encouraged to contact the study primary investigator or study coordinator on call. All enrolled subjects were also subsequently reviewed by the study DSMB to ascertain suitability. If arterial blood gases were not obtained, oxygen saturation (Spo 2 ) could be substituted for Pao 2 in the entry criteria but an Spo 2 /Fio 2 less than 250 (when Spo 2 < 97%) was necessary to qualify. A log of intubated patients with ALI/ ARDS was maintained at all institutions and the primary reason for not enrolling a potentially eligible patient recorded.
This study was a part of a combined adult and pediatric trial. Many of the participating hospitals admitted both adult and pediatric patients. A single research assistant commonly performed screening in those hospitals, but each hospital had separate adult and pediatric ICUs and appropriate subspecialists supervising the study in their respective areas.
Pediatric Study Arm
After initial demographic and qualifying data were entered on the study website, the participating site's pharmacy was automatically notified, and the pharmacist alone was provided the subject's assignment. The pharmacist then prepared the study drug, placing either air or calfactant in equal aliquots in two appropriately sized syringes, and the drug was delivered in an opaque container directly to the respiratory therapist and/or nurse for administration. Randomization was performed via the study website in blocks of four, and investigators were naïve to the randomization scheme. Subjects with an initial Pao 2 /Fio 2 or Spo 2 /Fio 2 less than 100, an oxygenation index (OI) > 30 (OI = Fio 2 • Paw • 100 / Pao 2 , where Paw represents the mean airway pressure), or who were immune compromised were considered higher risk and were independently randomized in order to assure an even distribution of more severely ill subjects in both groups.
The study intervention consisted of direct instillation of up to three doses of calfactant 12 hours apart versus sham treatment with air placebo. The dose was 30 mg calfactant (phospholipid concentration of 60 mg/mL) per centimeter of height or 100 mg/kg for infants weighing less than 10 kg. The treatment was delivered in two equally divided aliquots instilled directly into the airway using a small catheter placed down the endotracheal tube. Subjects were sequentially turned right side down and then left side down during drug or placebo administration. The investigators elected to use two position changes rather than the four used in our previous studies in consideration of the greater difficulty incurred positioning the larger adults and concurrent with the desire to use the same protocol for the adult and pediatric arms of the trial. The Fio 2 was increased to 1.0 during instillation, and ventilator settings were otherwise unchanged unless there were difficulties during the intervention, in the event of which the caregiver was allowed to hand ventilate the subject with 100% oxygen at whatever pressure was necessary to achieve adequate oxygenation. In previous studies, subjects were "hand ventilated" during administration, but the investigators elected in this study to perform the intervention while on the ventilator in the interest of minimizing variability in administration technique. Masking was accomplished by having the intervention performed by a nurse and/or respiratory therapist who was not otherwise involved in the care of the subject and who agreed to not divulge treatment assignment. Blood pressure, heart rate, and Spo 2 were continuously monitored and recorded every 5 minutes for 30 minutes after the intervention. Placebo subjects were treated identically with the exception that air was instilled rather than surfactant. To qualify for a subsequent dose, the subject had to demonstrate a 25% improvement in the Pao 2 / Fio 2 ratio (or Spo 2 /Fio 2 ) anytime in the 12 hours following the previous dose with no significant adverse effects attributable to the intervention. All subsequent interventions were delivered and masked using the same protocol.
Additional Protocols
As a precondition of trial participation, all investigators and their colleagues agreed in principle to follow guidelines modeled after the ARDS Network ventilator (14) and fluid guidelines (15) (Figs. 1 and 2 ). Investigators and study coordinators were instructed in both guidelines at the initial study visit and were given a supply of laminated cards with the fluid management and ventilator guidelines to distribute to colleagues caring for Calfactant in Acute Respiratory Distress Syndrome subjects in their institution. Since subjects were not required to have a central venous pressure (CVP) catheter for study entry, investigators were instructed to make judgments regarding fluid and/ or diuretic administration based on daily fluid balance if CVP measurements were not available. No attempt was made by the principal investigators to direct the fluid management of specific patients during the trial, but daily fluid balances (total fluid in minus total fluid out over 24 hr without consideration of insensible losses) were collected over the first 7 days after subject enrollment as a means of ascertaining comparability of fluid management in placebo and surfactant subjects. Similarly, no attempt was made to regulate the ventilator management of individual subjects. Ventilator settings were collected during the first 7 days of the enrollment to ascertain any significant differences in ventilator management between the study populations. Since the investigators postulated that avoidance of lung overdistention was the most vital aspect of the protocol, this was assessed by tracking the incidence of a peak ventilator pressure greater than 30 cm H 2 O and/or the use of a tidal volume greater than 8 cc/kg over the first 7 days after the study intervention.
All other aspects of care were left to the judgment of the attending physicians. Subjects discharged prior to 90 days were contacted by phone at 90 days to determine their health status.
Study Outcomes
The primary study outcome was all-cause mortality at 90 days after study entry. Secondary outcomes included ventilator-free days (VFDs) at 28 days, durations of ICU and hospital stay, and changes in oxygenation after the study intervention. Adverse events were followed throughout the period of hospitalization and assigned a relationship to the study intervention by the primary investigator at each site.
Data Collection
Ventilator settings, arterial blood gas results (if performed), and Spo 2 and end-tidal CO 2 (Etco 2 ) values were recorded at 1, 2, 4, 8, and 12 hours after each intervention and daily at approximately 08:00 hours for the first 7 days after study enrollment. Daily fluid balance was collected for the first 7 days as previously described. Demographics, as well as dates and times of intubation and extubation, and PICU and hospital admission and discharge were also collected. The duration of ventilation was calculated with successful extubation defined as 24 hours off mechanical ventilation and was computed as "VFDs at 28 days". Subjects dying before separation from mechanical ventilation were designated as having 0 VFDs. Subjects were followed daily until hospital discharge.
Adult Study Arm
Eligible patients older than 18 years were entered into the adult study with identical inclusion/exclusion criteria and using the same protocol. Although most of the participating hospitals included both adult and pediatric patients, all pediatric subjects were cared for in PICUs and all adult subjects in adult ICUs. These results will be reported in a separate article.
Statistical Methods
Sample size was calculated for the adult subject population. Assuming a 90-day mortality of 25% in the placebo group and 18% mortality in the calfactant group, enrolling 540 subjects in each group would give us an 80% power using an alpha (two sided) of 0.05. The pediatric arm was not powered for mortality because the required sample size was not considered attainable. However, the investigators assumed that approximately 300 pediatric subjects would be enrolled over the course of the projected 3 years of adult study. Using the results of our previous study with VFDs as our primary outcome, 300 subjects would yield 80% power for a 30% increase in VFDs; the attained sample size of 109 subjects would yield 80% power for a 50% increase in VFDs.
For
RESULTS
A total of 34,971 ventilated adult and pediatric subjects were screened, 2,949 of whom were identified as having direct ALI/ARDS. Of eligible subjects, 431 (15%) were entered into the trial, 110 children (< 18 years old) and 321 adults (Fig. 3) . The reasons for study exclusion are displayed in Figure 3 . One pediatric subject was randomized but not treated; consequently, these data are not available and are not included in this analysis. Fifty-three subjects received placebo and 56 were treated with calfactant surfactant. There were no significant differences in receiving a second or third intervention between groups; a second intervention was performed in 35% of surfactant subjects and 38% of placebo; only 5% of surfactant subjects received a third intervention compared with 13% in the placebo group.
Demographic data are found in Table 1 . There were no significant differences between surfactant and placebo groups with respect to age, gender, diagnoses, or severity of illness as estimated by PRISM III, risk level, or initial oxygenation disturbance (Pao 2 /Fio 2 or Spo 2 /Fio 2 ). Pneumonia (viral, bacterial, and aspiration) was the most common etiology of ALI/ ARDS. Twenty subjects were diagnosed with influenza; 14 had the H1N1 strain. A diagnosis of influenza was associated with 25% mortality (5/20) and H1N1 disease 21% (3/14) somewhat higher although not statistically different than the overall study mortality of 11% (12/109). The administration of surfactant was not associated with improvement in oxygenation relative to placebo, irrespective of whether Pao 2 /Fio 2 or Spo 2 /Fio 2 ratios were analyzed (Fig. 4,  A 
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and B).
As with our previous studies, surfactant administration was associated with few adverse effects. There were 22 adverse events believed possibly or probably related to the study intervention: four episodes of transient hypoxia (three surfactants, one placebo); bradycardia in two surfactant subjects; and one episode of leukopenia in a surfactant subject. The only serious adverse events were one pneumothorax and one pneumomediastinum, both in surfactant subjects. The pneumothorax required chest tube placement, but no intervention was required for the pneumomediastinum. All subjects with adverse events believed possibly or probably related to the study intervention recovered without sequelae.
Study outcomes are found in Table 2 . The primary study outcome was survival at 90 days, which was not different between the two groups. Overall mortality was 11%. Seven surfactant subjects died (12%) and five placebo subjects (9%), two after hospital discharge but before 90 days. VFDs and ICU-free days at 28 days were not statistically different, but surfactant subjects had significantly fewer hospital-free days (10.5 ± 7.7 vs 7.0 ± 7; p = 0.01). Multivariable regression adjusting for age, gender, risk strata, immune status, fluid balance, and PRISM score did not explain this difference (adjusted difference 3.5 d, p = 0.017). PICU categorical outcomes were not different. Neither ventilator nor fluid management differed between placebo and surfactant groups. Despite the conservative fluid management protocol, on average subjects accumulated nearly 2 L/M 2 over the first 7 days of the trial, and there was no difference between surfactant and placebo groups. Ventilator management was also comparable. Ventilator tidal volumes exceeded 8 mL/kg at least once in 58% of surfactant subjects and 57% of placebo subjects; ventilator peak pressures 
DISCUSSION
Unlike our previous studies, there appeared to be no benefit from surfactant administration. The lack of immediate improvement in oxygenation after surfactant administration was unexpected since this was a consistent finding in each of our three previous studies (10) (11) (12) . Although hospital-free days was the only statistically significant difference, the data also suggest that duration of ventilation and the need for PICU care may have been prolonged by surfactant treatment. The lack of acute benefit was particularly surprising because only a subgroup of ALI/ARDS subjects, those with "direct" lung injury, were included in this trial. This is the subgroup from our previous study that on post hoc analysis appeared to benefit most from calfactant (12) .
Our results of our calfactant trials in children have followed a path similar to that of the adult trials. After an initial negative trial of nebulized artificial surfactant (colfosceril palmitate, Exosurf) by Anzueto et al (17) , Gregory et al (18) reported improved oxygenation in a subgroup of adults with sepsis-induced ALI/ARDS using a natural surfactant (beractant, Survanta). A larger randomized controlled trial (RCT) using a recombinant surfactant containing surfactant protein C (Venticute) demonstrated improved oxygenation but no overall improvement in outcomes (19) . However, on post hoc analysis, the subgroup of subjects with direct lung injury had improved mortality. This prompted the investigators to proceed with a similar RCT focused on subjects with direct lung injury, but this study was stopped for futility (20) . The authors commented that their surfactant may have been inactivated by their preparation method, but no subsequent trials are currently planned. Finally, again after initial success in a smaller pilot study, the trial by Kesecioglu et al (21) using a porcine surfactant (HL-10) was stopped after the first interim analysis due to significant peridosing hypoxia and hypotension.
In this current trial with calfactant, there were three changes which, in retrospect, could have diminished the effectiveness of the treatment: 1) 60 mg phospholipid/mL rather than 35 mg phospholipid/mL calfactant preparation was used; 2) the instillation protocol did not include a lung recruitment maneuver; and 3) the instillation was performed in two rather than four aliquots with only two position changes rather than the four previous position changes (right side, head up, and head down; left side, head up, and head down). Each of these changes may have affected the distribution of the administered surfactant.
A more concentrated surfactant (60 mg/cc phospholipid vs 35 mg/cc) was used in this trial to decrease the liquid load on the lung from surfactant instillation. This was a concern for the adult study where the previous more dilute concentration would have necessitated as much as 200 cc of fluid surfactant which we feared might be associated with significant destabilization. In the interest of using a consistent protocol, this concentration was adopted for the pediatric arm as well. A lower liquid volume, however, may compromise surfactant distribution; larger surfactant volumes have been shown to have better distribution in experimental studies (22) (23) (24) .
The administration of the drug without a "recruitment maneuver" was another difference in this study protocol. Given the lack of experience with surfactant administration in adults, this was thought to be a simpler, more consistent, and safer approach than taking the subject off the ventilator and "hand ventilating" using higher pressures to deliver the surfactant, as we had in previous studies (10) (11) (12) . The investigators adopted this for the pediatric protocol in the interest of, again, having a uniform approach for both children and adults. Recruitment maneuvers alone have been reported to transiently improve oxygenation but with little sustained effect (25) (26) (27) . In our previous study, when subjects were hand ventilated at 10 cm H 2 O pressure above their ventilator peak pressure during instillation, both surfactant and placebo subjects demonstrated improved oxygenation, but the improvement was sustained only in the surfactant group (11). It is not established whether surfactant distribution is affected by a (28) reported that instillation of porcine surfactant (HL-10) produced increased lung aeration relative to placebo as demonstrated by CT scan 7 days after surfactant administration. During their administration, they performed a recruitment maneuver by increasing tidal volume to 12 mL/kg predicted body weight and positive endexpiratory pressure by 5 cm H 2 O for 30 minutes after instillation. In future studies, it would be of interest to investigate surfactant distribution when instilled with and without such a recruitment maneuver.
The final difference involved positioning during surfactant administration. Positioning theoretically enables gravity to assist in the distribution of the administered surfactant. This study included both children and adults, and the investigators were concerned that maneuvering larger adult subjects into four different positions might be technically difficult, would require more time, and might incur some risk. These have generally not been concerns in pediatric studies. All three of these changes may have resulted in poorer surfactant distribution. Exogenous surfactant is not likely to have an effect if it does not reach areas of the lung in which it is deficient or inhibited.
Entities, such as ALI/ARDS, which have multiple etiologies and a wide spectrum of concurrent medical issues are difficult targets for drug therapy. Improvements in supportive care have significantly improved patient outcomes, leaving fewer patients at risk for the efficacy endpoint of death. The unprecedented low mortality of the children in the placebo group in this trial made identification of a mortality benefit from lung surfactant unlikely. The lack of improvement in oxygenation observed in our previous studies may indicate that continuing advancements in supportive care for respiratory failure patients have made potential benefits of exogenous surfactant therapy moot.
We were heartened by the low mortality (11%) in the study population despite the relative severity of lung injury. This is considerably better than the 27% mortality in our previous study although the population of this study had somewhat lower average PRISM scores and Pao 2 /Fio 2 ratios at entry compared with the previous population (12) .
CONCLUSIONS
Calfactant instillation in pediatric patients with direct ALI did not improve oxygenation or longer term outcomes and was associated with prolonged hospital stay. Lack of benefit in this study relative to our previous studies may reflect differences in the study protocol which affected surfactant distribution. Future investigation should evaluate the effect of surfactant concentration and volume, patient positioning during administration, and recruitment maneuvers on surfactant distribution. Based on the results of this study, we cannot recommend administration of exogenous surfactant in patients with ALI/ARDS. 
